

Grifols expands its plasma collection network by acquiring 24 Biotest centers in the United States

- *Grifols acquires 100% of Biotest U.S. Corporation's shares for USD 286 million after obtaining approval by the Federal Trade Commission (FTC), the U.S. antitrust authority*
- *The transaction aligns with Grifols' corporate strategy and enables the company to reinforce its donation-center expansion plan, initiated in 2015, to increase and diversify its access to its main raw material used to produce plasma-derived therapies*
- *Grifols is the worldwide leader in plasma collection, with nearly 250 centers in the United States and Europe following the acquisition of the German firm Haema. Its strategic plan also includes building and managing plasma centers in China*

Barcelona (Spain), August 1, 2018.- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS) has closed a transaction to acquire 24 plasma donation centers in the United States operated by Biotest Pharmaceuticals Corp., a wholly-owned subsidiary of Biotest US Corporation, for USD 286 million (EUR 244 million). Grifols financed the transaction with its own resources, without issuing debt.

Following this acquisition, Grifols will own 249 plasma donation centers to ensure access to its main raw material and increase its supply of plasma proteins used for therapeutic purposes. All of the newly acquired plasma donation centers are licensed by the U.S. Food and Drug Administration (FDA) and European health authorities. In 2017, these acquired plasma donation centers collected approximately 850,000 liters of plasma.

The agreement includes 24 collection centers, 2 plasma centers under construction and a series of other assets, among them, existing working capital amounting to approximately USD 40 million.

The transaction has been approved by all competent regulatory authorities.

By expanding and diversifying its network of donation centers, Grifols reinforces its global leadership position in plasma collection in alignment with its strategic plan. This transaction, coupled with the 2016-2021 capital investment plans for the Bioscience Division (endowed with more than EUR 500 million) will enable Grifols to meet the projected growing demand for plasma-derived medicines.

GRIFOLS

Grifols currently owns 214 centers in the U.S. and 35 in Europe following the acquisition of Haema, Germany's largest independent network of donation centers. Its overall strategy also includes an agreement to build and manage plasma donation centers in China with Boya Bio-Pharmaceutical, a leading Chinese manufacturer of plasma-derived medicines.

Osborne Clarke, S.L.P. acted as legal advisor for the transaction.

Investors contact:

Investor Relations Department

inversores@grifols.com - investors@grifols.com

Phone number: +34 93 571 02 21

Media contact:

Raquel Lumbreras raquel_lumbreras@duomocomunicacion.com

Borja Gómez borja_gomez@duomocomunicacion.com

Duomo Comunicación - Grifols Press Office

Phone number: +34 91 311 92 89 - +34 91 311 92 90

About Grifols

Grifols is a global healthcare company with more than 75 years of legacy dedicated to improving the health and well-being of people around the world. Grifols produces essential plasma-derived medicines for patients and provides hospitals and healthcare professionals with the tools, information and services they need to help them deliver expert medical care.

Grifols' three main divisions – Bioscience, Diagnostic and Hospital – develop, produce and market innovative products and services that are available in more than 100 countries.

With a network of 249 plasma donation centers, Grifols is a leading producer of plasma-derived medicines used to treat rare, chronic and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of diagnostic products designed to support safety from donation through transfusion. The Hospital Division provides intravenous (IV) therapies, clinical nutrition products and hospital pharmacy systems, including systems that automate drug compounding and control drug inventory.

Grifols is headquartered in Barcelona, Spain and has 18,300 employees in 30 countries.

In 2017, sales exceeded 4,300 million euros. Grifols demonstrates its strong commitment to advancing healthcare by allocating a significant portion of its annual income to research, development and innovation.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the US NASDAQ via ADRs (NASDAQ:GRFS).

For more information, visit grifols.com.

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are “future projections and assumptions”. Words and expressions such as “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “will seek to achieve”, “it is estimated”, “future” and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.